358 related articles for article (PubMed ID: 7910219)
1. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
2. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
[TBL] [Abstract][Full Text] [Related]
3. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation.
Hill BT; Whelan RD; Hurst HC; McClean S
Cancer; 1994 Jun; 73(12):2990-9. PubMed ID: 7911070
[TBL] [Abstract][Full Text] [Related]
4. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Volm M; Kästel M; Mattern J; Efferth T
Cancer; 1993 Jun; 71(12):3981-7. PubMed ID: 8099529
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer.
Rybárová S; Vecanová J; Hodorová I; Mihalik J; Čižmáriková M; Mojžiš J; Solár P; Benický M; Adamkov M; Mirossay L
Med Sci Monit; 2011 Dec; 17(12):BR354-63. PubMed ID: 22129893
[TBL] [Abstract][Full Text] [Related]
6. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.
Charpin C; Vielh P; Duffaud F; Devictor B; Andrac L; Lavaut MN; Allasia C; Horschowski N; Piana L
J Natl Cancer Inst; 1994 Oct; 86(20):1539-45. PubMed ID: 7932810
[TBL] [Abstract][Full Text] [Related]
7. Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients.
Schneider J; Romero H
Anticancer Res; 1995; 15(3):1117-21. PubMed ID: 7645934
[TBL] [Abstract][Full Text] [Related]
8. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
9. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression.
Coronado PJ; Vidart JA; Lopez-asenjo JA; Fasero M; Furio-bacete V; Magrina J; Escudero M
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):103-8. PubMed ID: 11516808
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and tumor progression.
Benchimol S; Ling V
J Natl Cancer Inst; 1994 Jun; 86(11):814-6. PubMed ID: 7910218
[No Abstract] [Full Text] [Related]
11. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
12. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Holzmayer TA; Hilsenbeck S; Von Hoff DD; Roninson IB
J Natl Cancer Inst; 1992 Oct; 84(19):1486-91. PubMed ID: 1359152
[TBL] [Abstract][Full Text] [Related]
13. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.
Clarke R; Currier S; Kaplan O; Lovelace E; Boulay V; Gottesman MM; Dickson RB
J Natl Cancer Inst; 1992 Oct; 84(19):1506-12. PubMed ID: 1359153
[TBL] [Abstract][Full Text] [Related]
14. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
15. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.
Linn SC; Honkoop AH; Hoekman K; van der Valk P; Pinedo HM; Giaccone G
Br J Cancer; 1996 Jul; 74(1):63-8. PubMed ID: 8679460
[TBL] [Abstract][Full Text] [Related]
16. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
17. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections.
Nielsen AL; Nyholm HC
Am J Clin Pathol; 1994 Jul; 102(1):76-9. PubMed ID: 7913577
[TBL] [Abstract][Full Text] [Related]
18. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry.
Schneider J; Rubio MP; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
Eur J Cancer; 1994; 30A(4):504-8. PubMed ID: 8018409
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors.
Chang K; Ding I; Kern FG; Willingham MC
J Histochem Cytochem; 1991 Sep; 39(9):1281-7. PubMed ID: 1680897
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
